A new study linked weight loss drugs known as semaglutides (Ozempic is one) to a lower risk of opioid overdoses. Doctors tell 'WH' why the connection exists.

The term "Ozempic face" is not a medical term, but some use it to describe this type of appearance after weight loss. Here what's fact and fiction.

James Corden revealed that he tried taking Ozempic for weight loss and then explained the reason he didn’t have any results with the trendy medication.

Television presenter James Corden has this week admitted to having used Ozempic as a means of losing weight, but insisted that the controversial appetite-suppressing drug 'didn't work' for him.

James Corden revealed that he gave Ozempic a try to help with weight loss, but soon found that his relationship with food had little to do with how hungry he was or wasn’t.

Lizzo says she's "fine both ways" as she shares updates on her fitness journey and denies using Ozempic to lose weight.

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel full. When the drug interacts with a receptor in the stomach, patients feel full sooner and for a longer period of time after eating. The drug does not cause weight loss directly – instead, it makes you want to eat less.

James Corden is among the celebrities who have tried Ozempic for weight loss, but he didn’t have the life-changing results that some people report. “I tried Ozempic, and it won’t be surprising to you when you look at me now,

WeightWatchers CEO Sima Sistani abruptly stepped down Friday after a two-year stint that included a controversial embrace of weight-loss drugs like Ozempic and Wegovy. Sistani pushed the 61-year-old company — famous for in-person meetings and portion control — to buy a telehealth platform that connected patients with doctors who can prescribe the popular obesity medications.

Sima Sistani helped push the company into the GLP-1 drug space with the $106 million acquisition of Sequence.

International said Friday that CEO Sima Sistani is stepping down immediately. She will be replaced by Tara Comonte, a board member and the former CEO of Shake Shack (SHAK), who was appointed as interim chief executive effective immediately.